New Study Validates Masimo’s SpHb – Analyst Blog

Masimo Corporation (MASI) recently presented results from a fresh study that demonstrated the clinical accuracy of its noninvasive and continuous hemoglobin (SpHb) monitoring device.

 

The study titled “Comparison Between a New Noninvasive Continuous Technology of Spectrophotometry-based and RBC Count for Hemoglobin Monitoring During Surgery with Hemorrhagic Risk”, was presented at the European Society of Anesthesiology Annual Congress in Helsinki. It compared accuracy of results obtained from Masimo SpHb with hemoglobin measured in blood samples obtained through invasive techniques. The patient universe consisted of 20 participants undergoing high blood-loss during surgery. For study purposes, SpHb and invasive hemoglobin measurements were taken at the same time, at the start and conclusion of clinical intervention, and before and after blood transfusion.

 

The study, conducted under real-life conditions, validated the original tests that were earlier conducted by Masimo.

 

Masimo’s SpHb is part of its Rainbow platform that provides, among other parameters, a continuous and noninvasive measurement of total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, Pleth Variability Index, acoustic respiration rate, Measure-Through Motion, pulse rate and perfusion index.

 

Masimo’s breakthrough, noninvasive monitoring technologies can be integrated into a wide range of multi-parameter and multi-use monitoring devices. Introduced in 1995, the Masimo SET has a well documented track record for providing reliable measurement of SpO2 and pulse rate.

 

In 2005, Masimo launched its Rainbow SET Pulse CO-Oximetry technology, which permits noninvasive and continuous monitoring of additional blood constituents that earlier required invasive procedures.

 

Subsequently, in 2009, Masimo introduced Rainbow SET Accoustic Monitoring for continuous noninvasive monitoring of acoustic respiration rate. Masimo generated total revenue of $98.7 million in the first quarter of 2010 versus $85.5 million in the year-ago period.

 

We currently have a Neutral rating on Masimo.